Evaluating the effect of long-term idebenone treatment on respiratory morbidity in patients with Duchenne muscular dystrophy (DMD)

O. Mayer (Philadelphia, United States of America), M. Leinonen (Pratteln, Switzerland), L. Servais (Liege, Belgium), C. Straathof (Leiden, Netherlands), U. Schara (Essen, Germany), T. Voit (London, United Kingdom), E. Mercuri (Rome, Italy), G. Buyse On Behalf Of The Syros Investigators (Leuven, Belgium)

Source: International Congress 2019 – Rare and ultra-rare diseases and the lungs: updates and new perspectives
Session: Rare and ultra-rare diseases and the lungs: updates and new perspectives
Session type: Oral Presentation
Number: 5330
Disease area: -

Congress or journal article abstractWebcastSlide presentationE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
O. Mayer (Philadelphia, United States of America), M. Leinonen (Pratteln, Switzerland), L. Servais (Liege, Belgium), C. Straathof (Leiden, Netherlands), U. Schara (Essen, Germany), T. Voit (London, United Kingdom), E. Mercuri (Rome, Italy), G. Buyse On Behalf Of The Syros Investigators (Leuven, Belgium). Evaluating the effect of long-term idebenone treatment on respiratory morbidity in patients with Duchenne muscular dystrophy (DMD). 5330

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: